descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 15 Aug 2011 English Publisher:Oxford University Press (OUP)Journal:American Journal of Health-System Pharmacy, volume 68, pages 1,495-1,495 (issn: 1079-2082, eissn: 1535-2900,

Authors: Christine M, Cheng; Megan R, McCurdy; Heather A, Wong; Steven R, Kayser;

doi: 10.2146/ajhp110178

pmid: 21817080

Pros and cons of dabigatran

- Summary
- Subjects
- Metrics

Abstract

As described in this issue of AJHP (see page 1506), dabigatran etexilate is the first oral direct thrombin inhibitor and the first oral anticoagulant since warfarin to become available in the United States. In contrast to warfarin, fixed twice- daily dosing of dabigatran offers predictable

Related Organizations

University of California, San Francisco
United States

Keywords

Pyridines, Thrombin, Anticoagulants, Humans, Benzimidazoles, Dabigatran

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	5
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average